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The link between obesity and hypertension is well known, but there are still many 
questions to be answered: Is abdominal adiposity rather than overall obesity more 
closely associated with high blood pressure? Is obesity an independent cardiovascu-
lar risk factor even if not combined with hypertension? Can obesity be metabolically 
benign? To what extent weight reduction is expected to contribute to the management 
or the primary prevention of hypertension? Are there compelling indications and/or 
contraindications to the use of specific classes of antihypertensive drugs for the phar-
macological treatment of obesity hypertension? Consequently, the present editorial 
seeks to answer these questions by briefly reviewing the current state of knowledge 
of the association of obesity with hypertension.
Several tools are used to estimate obesity. The body mass index (BMI), or Quetelet 
index, is a statistical measurement which compares a person’s weight and height. BMI 
is body weight in kilograms divided by the height in meters squared, expressed as 
weight (in kg)/height (m2). Overweight is defined as a BMI >25, obesity as a BMI >30, 
and morbid obesity is a BMI >35. Abdominal obesity is the accumulation of visceral 
fat resulting in an increase in waist size. It is often referred to as central, visceral, 
male-type or android obesity vs. female-type or gynoid obesity with a preferential 
gluteofemoral distribution. Abdominal obesity is diagnosed by a waist circumference 
>102 cm in men, and >88 cm in women or by a waist-to-hip ratio >0.95 in men and 
>0.85 in women.
As early as in 1980, in the second National Health and Nutrition Examination 
Survey (NHANES II), it was noted that the prevalence of hypertension was 2.9 times 
higher in obese than in non-obese adult Americans.1 The Third National Health 
and Nutrition Examination Survey (NHANES III) conducted from 1988 to 1994 
revealed a similar linear relationship despite a lower prevalence of hypertension.2 
BMI was recently found to be positively associated with blood pressure even in active, 
American veteran football players.3 In a cross-sectional analysis of adults enrolled in 
NHANES 1999-2004, the odds ratio for hypertension for every 5-unit increase in BMI 
was 1.45 (95% CI 1.39-1.52). Although obesity was associated with hypertension in 
all age groups and both sexes, the odds for hypertension associated with obesity were 
relatively higher in younger people. With regard to hypertension subtypes, increasing 
BMI was a significant predictor of isolated diastolic hypertension or systodiastolic 
hypertension as opposed to isolated systolic hypertension. Isolated systolic hyperten-
sion represented a minority of hypertension cases in obese men, but remained the 
most prevalent type in obese women.4
There is substantial evidence that in addition to BMI, both waist circumference 
and waist-to-hip ratio are correlated with blood pressure, even after adjustment for 
BMI.5 The associations of BMI and waist circumference with systolic and diastolic 
blood pressure and their possible interactions with gender and age were assessed in 
a cohort of 10,928 non-smoking and never treated for hypertension adults, recruited 
from all regions of Greece during 1994–1999, within the context of the European 
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Prospective Investigation into Cancer and nutrition (EPIC).6 
Both BMI and waist circumference were found to be important 
predictors of systolic and diastolic blood pressure among both 
men and women. Among men, however, waist circumference 
appeared to be more important than BMI, whereas the op-
posite was apparently true for women. The differential effects 
of BMI and waist circumference on blood pressure by gender 
were evident among individuals older than 55 years, while 
among younger individuals BMI and waist circumference had 
comparable effects in both sexes. On the other hand, when 
waist-to-hip ratio was used instead of waist circumference and 
hip circumference, BMI became considerably more important 
than waist-to-hip ratio among both men and women.
Overweight and obese individuals of both genders have 
an increased risk of coronary heart disease and heart failure.7 
Nevertheless, since obesity is associated with an increased 
incidence of hypertension, dyslipidemia and type 2 diabetes, 
it has been postulated that the increased risk among obese 
subjects is related primarily to the influence of the associ-
ated risk factors and not to the obesity per se. In a French 
cohort of 139,562 men and 104,236 women, aged 18 to 95 
years, overweight subjects without associated risk factors did 
not have an increased risk of cardiovascular mortality when 
compared with subjects with a body mass index <25 kg/m2. 
Mortality data for a mean follow-up period of 14.1±0.2 years 
were available for this population. The risk of cardiovascular 
death increased significantly when overweight was associ-
ated with hypertension alone. By contrast, the association of 
overweight with diabetes alone or hypercholesterolemia alone 
did not increase the risk. The authors conclude that the only 
reason for considering overweight as a major cardiovascular 
risk determinant is because it increases the prevalence of as-
sociated risk factors, especially hypertension.8
This conclusion, however, was based on analysis of the 
influence of body weight over a rather short period of fol-
low-up and may not have conveyed the true impact of disease 
risk. When the influence of relative weight (the ratio of actual 
weight to desirable weight x100) on the 26-year incidence of 
cardiovascular disease was examined in the 2,252 men and 
2,818 women of the original Framingham cohort, ages 28-62 
years, who were free of clinically recognizable cardiovascular 
disease at the first study examination, the degree of obesity was 
found to be an important long term predictor of the incidence 
of coronary disease (both angina and coronary disease other 
than angina), coronary death and congestive heart failure in 
men independent of age, cholesterol, systolic blood pressure, 
cigarette smoking, left ventricular hypertrophy and glucose 
intolerance. Relative weight in women was also positively 
and independently associated with coronary artery disease, 
stroke, congestive heart failure, and coronary and cardiovas-
cular disease death. The impact of weight on the incidence 
of cardiovascular disease was similar in those younger than 
40 years and 40-49 years, but greater in these two age groups 
combined than in those older than 50 years. In a subgroup 
of 629 men and women younger than 50 years who were nor-
motensive, had cholesterol levels less than 250 mg/dl, did not 
smoke cigarettes, and had no evidence of glucose intolerance 
or electrocardiographic left ventricular hypertrophy, the inci-
dence of cardiovascular disease rose with increasing weight 
in both genders, but the gradient of risk was clearly steeper 
in males than females.9
On the basis of evidence from early studies indicating that 
abdominal adiposity, as measured by waist circumference or 
waist-to-hip ratio, is an independent risk factor for cardiovas-
cular disease,10-12 waist circumference >102 cm in men, and 
>88 cm in women has been advocated as risk factor by recent 
hypertension treatment guidelines.13,14 INTERHEART, a 
case-control study of acute myocardial infarction, conducted 
in 52 countries, including Greece, with 15,152 cases and 14,820 
controls, was designed to examine the relationship of smoking, 
diabetes, hypertension, blood apolipoproteins, obesity, waist 
circumference, and psychosocial factors to myocardial infarc-
tion. In this study, the age- and region-adjusted odds ratios 
(95% CI) for risk of acute myocardial infarction for a change 
of 1 SD in waist circumference adjusted for BMI measurement 
was calculated to be 1.24 (1.19-1.25) for men and 1.21 (1.17-
1.25) for women. The odds ratios (95% CI) for a change of 
1 SD in BMI adjusted for waist circumference was relatively 
lower, especially for men (1.13 [1.09-1.17] as contrasted to 1.20 
[1.16-1.24] for women).15
The concept of “benign obesity” has been used for more 
than 20 years to suggest that a considerable proportion of 
overweight and obese adults may not be at increased cardio-
vascular risk from their excess weight. Recent analysis of the 
data from 5,440 participants in the National Health and Nutri-
tion Examination Surveys (NHANES) 1999-2004 showed that 
23.5% of normal-weight adults were metabolically abnormal, as 
evidenced by the presence of hypertension, insulin resistance, 
raised triglycerides, fasting plasma glucose, and C-reactive 
protein, and low high-density lipoprotein, whereas 51.3% of 
overweight adults and 31.7% of obese adults were metabolically 
healthy. Factors associated with hypertension and metabolic 
abnormalities among normal-weight individuals were older 
age, lower physical-activity levels, and larger waist circumfer-
ence, and factors associated with lack of such abnormalities 
among overweight and obese individuals were younger age, 
non-Hispanic black race/ethnicity, higher leisure-time physi-
cal-activity levels, and smaller waist circumference.16
Abdominal obesity has long been known to correlate with 
insulin resistance and many investigators have claimed that 
excess visceral fat is more strongly associated with insulin 
resistance than any other adipose tissue compartment. Results 
from another recent study, however, suggest that visceral fat, 
classically measured through its surrogate waist circumference, 
may in fact be a relatively weak predictor of insulin resis-
tance.17 The researchers investigated 314 subjects measuring 
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parameters, such as total body, visceral and subcutaneous fat 
with magnetic resonance tomography and fat in the liver and 
skeletal muscle with proton magnetic resonance spectroscopy, 
as well insulin sensitivity and carotid intima thickness. They 
found that altogether, 10% of the study population and 25% 
of the obese subjects had a high insulin sensitivity phenotype 
or “metabolically benign obesity”. In the above study, obese 
but insulin-sensitive patients had a lower fat accumulation in 
skeletal muscle and particularly in the liver and lower intima-
media thickness of the common carotid artery compared to 
obese, insulin-resistant patients. The authors conclude that 
a metabolically benign obesity that is not accompanied by 
insulin resistance and early atherosclerosis exists in humans. 
An accompanying editorial, however, points out that because 
risk factors and not outcomes were the end points in the above 
study (although carotid intima-media thickness is a reasonable 
surrogate measure of end-organ damage), insulin measure-
ments are still not justified as a tool in the evaluation of the 
obese patient and assessment of cardiovascular risk should 
rely on BMI calculation and waist circumference.18
In hypertension treatment guidelines, weight loss is pro-
posed as the most effective non-pharmacological means for 
lowering blood pressure in obese hypertensives, as well as for 
decreasing the dose of antihypertensive medications required 
to control blood pressure in overweight individuals.13,14 Weight 
loss has also been advocated as an effective nonpharmacologic 
means for the primary prevention of hypertension in the popu-
lation at large. In this respect, the results of an observational 
study on the surviving members of the Framingham cohort 
suggest that a weight loss of 6.8 kg or more can reduce the 
long-term risk of hypertension by 21% to 29%.19 An early 
meta-analysis of 12 controlled intervention trials showed a 
reduction in systolic blood pressure and diastolic blood pressure 
of -2.4 and -1.5 mm Hg per kilogram weight loss, respectively.20 
However, only half of the studies in this meta-analysis were 
randomized. A more recent meta-analysis of 25 randomized 
controlled trials comprising 4,874 participants from different 
ethnic populations showed a blood pressure reduction of -4.4/-
3.6 mm Hg (95% CI, -5.93 to -2.95/-4.88 to -2.25) for a net 
weight reduction of -5.1 kg (95% CI, -6.03 to -4.25) by means 
of energy restriction, physical activity, or both. The effect on 
diastolic blood pressure was significantly larger in populations 
taking antihypertensive drugs than in untreated populations 
(-5.31 mm Hg [95% CI, -6.64 to -3.99] vs -2.91 mm Hg [95% 
CI, -3.66 to -2.16]).21
In general, hypertension in obese patients is less responsive 
to various antihypertensive medications. Current guidelines 
for the management of hypertension make no specific recom-
mendations for treatment of patients with obesity hypertension 
that go beyond recommending weight loss. The reason for this 
lack of compelling indications and contraindications is perhaps 
the fact that although there is some evidence that certain anti-
hypertensive drugs used as monotherapy may be more effective 
than others in lowering blood pressure in obese patients, no 
hard-endpoint studies in obese hypertensive patients have been 
reported to date.22 In addition, in most large intervention trials 
the average BMI of participants barely exceeds 30 kg/m2, and 
although some of them may have included several overweight 
or obese patients, sub-analyses for these subgroups have not 
been presented so far.23
In conclusion: (a) the prevalence of hypertension is much 
higher in obese than in non-obese adults, particularly in 
younger people; (b) isolated systolic hypertension represents a 
minority of hypertension cases in obese men, but remains the 
most prevalent type in obese women; (c) among men older than 
55 years waist circumference appears to be a more important 
predictor of hypertension than BMI, whereas the opposite is 
true for women of the same age group; (d) obesity as estimated 
by BMI, as well as abdominal adiposity as measured by waist 
circumference seem to be independent cardiovascular risk 
factors, especially in males; (e) about half of overweight and 
30% of obese adults may be not at increased cardiovascular 
risk from their excess weight, but is uncertain whether this 
“benign obesity” phenotype is expressed by insulin sensitivity 
or by a particular body fat distribution; (f) a reduction of at 
least 4/3 mm Hg in the general population and a significantly 
larger effect in patients taking antihypertensive drugs can be 
expected by a weight reduction of about 5 kg; (g) there is lack 
of evidence from antihypertensive trials regarding the most 
appropriate antihypertensive drugs for the obese hypertensive 
patient.
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